PMID- 34285180
OWN - NLM
STAT- MEDLINE
DCOM- 20210722
LR  - 20211204
IS  - 1941-5923 (Electronic)
IS  - 1941-5923 (Linking)
VI  - 22
DP  - 2021 Jul 21
TI  - A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination.
PG  - e931478
LID - 10.12659/AJCR.931478 [doi]
AB  - BACKGROUND Immune thrombocytopenic purpura (ITP) is an immune response that 
      destroys platelets and increases the risk of bleeding, which can range from 
      bruising to intracranial hemorrhage. ITP is a known complication of coronavirus 
      disease 2019 (COVID-19). In the first studies of the BNT162b2 messenger RNA 
      (mRNA) COVID-19 vaccine, there were no reports of ITP and the incidence of 
      serious adverse events (AEs) was low overall. Here, we present a case of ITP as a 
      complication of the BNT162b2 mRNA COVID-19 vaccine. CASE REPORT Three days after 
      receiving a second dose of the BNT162b2 mRNA COVID-19 vaccine, a 39-year-old 
      woman presented with a petechial rash on her trunk, legs, and arms, and fatigue 
      and muscle aches. At the time of her hospital admission, her platelet count was 
      1000/microL. A peripheral smear showed profound thrombocytopenia. During the course 
      of the patient's hospitalization, she was treated with 2 units of platelets, 2 
      infusions of i.v. immunoglobulin, and i.v. methylprednisolone. Her platelet count 
      increased to 92 000/microL on the day of discharge and she was prescribed a tapered 
      dose of oral prednisone. One day later, her rash had resolved and her platelet 
      count was 243 000/microL. The patient recovered completely with no complications. 
      CONCLUSIONS ITP should be considered a severe AE of the BNT162b2 mRNA COVID-19 
      vaccine. Knowing the early signs and symptoms of ITP will become increasingly 
      important as more of the population receives this vaccine. Quick diagnosis and 
      management are essential to avoid life-threatening bleeding.
FAU - King, Eleanor R
AU  - King ER
AD  - Department of Family Medicine, Ascension Providence Rochester Hospital, 
      Rochester, MI, USA.
FAU - Towner, Elizabeth
AU  - Towner E
AD  - Department of Family Medicine and Public Health Sciences, Wayne State University, 
      Detroit, MI, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20210721
PL  - United States
TA  - Am J Case Rep
JT  - The American journal of case reports
JID - 101489566
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (RNA, Messenger)
RN  - N38TVC63NU (BNT162 Vaccine)
SB  - IM
MH  - Adult
MH  - BNT162 Vaccine
MH  - *COVID-19
MH  - COVID-19 Vaccines
MH  - Female
MH  - Humans
MH  - *Purpura, Thrombocytopenic, Idiopathic
MH  - RNA, Messenger/genetics
MH  - SARS-CoV-2
MH  - *Thrombocytopenia/etiology
MH  - Vaccination/adverse effects
PMC - PMC8311388
COIS- Conflict of interest: None declared Conflict of interest None.
EDAT- 2021/07/22 06:00
MHDA- 2021/07/23 06:00
PMCR- 2021/07/21
CRDT- 2021/07/21 05:49
PHST- 2021/07/21 05:49 [entrez]
PHST- 2021/07/22 06:00 [pubmed]
PHST- 2021/07/23 06:00 [medline]
PHST- 2021/07/21 00:00 [pmc-release]
AID - 931478 [pii]
AID - 10.12659/AJCR.931478 [doi]
PST - epublish
SO  - Am J Case Rep. 2021 Jul 21;22:e931478. doi: 10.12659/AJCR.931478.